DMAA · Drugs Made In America Acquisition Corp
United States · RS rating 71 · As of 2026-10-14
| Price | 10.85 USD |
|---|---|
| 1-day change | -0.1% |
| RS rating (overall / 1M / 3M / 12M) | 71 / 70 / 72 / 54 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 34 / 34 / 25 |
| Industry group (rank) | Finance-Blank Check (35) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +0.4% |
| Market cap (USD) | $355.4M |